These are a couple of old news items that I'm catching up with.
Kamada Changes Phase-II Alpha-1 Antitrypsin (AAT) Study
Kamada has announced a major change to their Phase-II trial of AAT. Although there are several AAT trials underway, this is the farthest along, and the largest. You can read my previous blogging here:
AAT is an anti-inflammatory / immunomodulatory drug, which the body makes naturally, and which is already FDA approved for people who have a rare condition where they don't make enough of it on their own. Using AAT to treat type-1 diabetes is based on the idea that one of AAT's effects (lowering inflammation, immune modulation, or wound healing) can cure/prevent/treat the disease.
Prior to the change: The trial would collect data on 180+ people for two years. The first half would be double blind, but at the half way point (90 people and 1 year) the data would be analysed unblinded, to check for safety and do futility analysis. Results from the completed trial probably would not be published until 2019, maybe longer, depending on how long recruiting took.
After the change: The 60 patients enrolled by the end of 2015 will be followed for one year, and then results will be published, probably in 2017.
What does this mean? It means we will see results from this trial quicker than originally planned, but it also means there will be less data. Is this good or bad? I thought about this question quite a bit, and there are two ways to answer that question. From my point of view, this is good, because it will mean that we have results faster. It is true they will not be as definitive, but my gut reaction is that if there is clear good news, then it will show up even in a 60 person study. The only danger is that with 60 people, the results will not be clear. But my belief is that if they are not clear with 60 people, then the answer is "no". I think it's unlikely that a drug which is so-so with 60 people is going to show as a cure with 120 or 180 people.
Of course, another question is, do these changes mean that Kamada thinks the drug is working, or do they mean Kamada thinks the drug is failing? My answer to that is "I don't know". The trial is double blind, so officially Kamada should not know anything about the outcome. Even if they did, good results could motivate them to speed things up, but so could bad results (to lower expenses). I don't see a good way to "read meaning" into a shorter trial.
In the non-scientific world, it could mean that the company is running low on money, or that it is harder than expected to recruit people for the study. As originally designed, this study would require 180+ honeymooners to enroll in one country: Israel. That's a lot of fish to pull out of a small fishing hole. (My very "back of the envelope" calculations suggest that about 350 people are diagnosed with type-1 in Israel per year, so you'd need to get about half of them to enroll. If you recruited for two years then "only" 1/4 of everyone diagnosed in the entire country would need to sign up. That is hard.)
Press release: http://www.businesswire.com/news/home/20151202005422/en/Kamada-Update-Alpha-1-Antitrypsin-Development-Newly-Diagnosed
About the inhaled version (being tested for a different disease):
AAT is already approved as an intravenous injection for treating AAT deficiency. This is not the same type of injection as insulin; it generally requires a trip to a clinic for treatment. However, Kamada is also testing an inhaled form to treat AAT deficiency. If this is approved, and if AAT is found to work for type-1 diabetes, then having different forms will be convenient. They have finished enrolling their inhaled AAT study, which is a good milestone:
Albiglutide Starts a Phase-II Trial
Albiglutide (tradenames Eperzan and Tanzeum) was approved in both the USA and the EU in 2014. It is a Byetta-like drug, designed to be used once per week, so the dosing is more like Victoza. Like both of those drugs, Albiglutide is part of a large class of drugs called GLP-1 inhibitors. All of these drugs are commonly used by people with type-2 diabetes. It is not clear to me why it would cure type-1, but GlaxoSmithKline is testing it in type-1 diabetics, and it might improve A1c numbers.
This trial involves about 68 people, of whom 51 will get the drug and 17 will be in the placebo group.
The trial will take about 17 months per person. Two months of pre-treatment screening, 12 months of treatment, and three months of post treatment monitoring. They started in November 2014 and hope to finish by December 2016.
They will be recruiting people at about 29 different sites, in five different countries (France, UK, Germany, Italy, and Spain). See the complete list in the clinical trial record below.
Clinical Trial Record: https://clinicaltrials.gov/ct2/show/NCT02284009
My plan is to follow this study, and see if this drug turns out to be a promising treatment, a promising cure, or neither. If it doesn't show cure potential, I will stop covering it.
If this drug does prove useful in curing (or even treating) type-1 diabetes, there are several other widely available drugs in the same category which could be tested (some are available for off label use immediately). In addition to Victoza and Byetta there are: Bydureon, Dulaglutide, and Lixisenatide.
publicjoshualevy at gmail dot com
All the views expressed here are those of Joshua Levy, and nothing here is official JDRF or JDCA news, views, policies or opinions. My daughter has type-1 diabetes and participates in clinical trials, which might be discussed here. My blog contains a more complete non-conflict of interest statement. Thanks to everyone who helps with the blog.